ANCA ASSOCIATED VASCULITIS
Clinical trials for ANCA ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control TerminatedThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising vasculitis drug trial halted early
Disease control TerminatedThis study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control TerminatedThis study tested whether hydroxychloroquine, a drug used for lupus and arthritis, could help control ANCA vasculitis—a group of autoimmune diseases that cause blood vessel inflammation. Adults with mild disease activity were randomly assigned to receive hydroxychloroquine or a p…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Blood test may help some ANCA patients skip unnecessary drugs
Knowledge-focused TerminatedThis study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initia…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC